Kuhnil to sign an exclusive distribution of anticancer drug with Regulon Inc.

Kuhnil announced on Sept. 6 that an agreement was signed with Regulon Inc. for the exclusive distribution of an anti-cancer drug, Lipoplatin, in Korea, which is a lipsome preparation of Cisplastin, showing better profiles of its toxicity.

Regulon Inc. said that Lipoplatin provided a better quality of life for the patients with less adverse reactions such as low peripheral neuropathy, renal ...